Insights & news

Publication of Regulation on Health Technology Assessment

  • 22/12/2021
  • Articles

The Official Journal of the European Union publishes today the Regulation on Health Technology Assessment (HTA) (Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU; see, attached copy). The publication follows the Regulation’s approval in second reading by the European Parliament on 13 December 2021 and its endorsement by the Council of the European Union on 9 November 2021 (see, Van Bael & Bellis Life Sciences News & Insights of 15 December 2021 and 12 November 2021).
 
While the Regulation on HTA will enter into force on 11 January 2022, i.e., “the twentieth day following that of its publication in the Official Journal of the European Union” (see, Article 36(1) of the Regulation), it will only apply from 12 January 2025 (see, Article 36(2) of the Regulation). As noted earlier, the long interim period will be used to set up the organisational framework contemplated by the Regulation on HTA and to adopt a series of implementing measures. The first meeting of the yet to be established Coordination Group of Member State representatives is scheduled to convene in June 2022. In practical terms, no joint work among Member States pursuant to the Regulation will occur before the first quarter of 2025.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 11/01/2022
    • Articles

    Clinical Trials Regulation - Cooperation of Member States in Safety Assessment of Clinical Trials

    The European Commission published yesterday a Commission Implementing Regulation (EU) 2022/20 of 7 January 2022 “laying down rules for the application of Regulation (EU) No 536/2014 of the European Parliament and of the Council as regards setting up the rules and procedures for the cooperation of the Member States in safety assessment of clinical trials” (the Regulation; see, attached copy).

    Read more
    • 10/01/2022
    • Articles

    EFPIA Publishes Regulatory Wish-List Ahead of European Commission Proposals for Pharmaceutical Reform Due in 2022

    As you know, as part of its wide-ranging EU Pharmaceutical Strategy, the European Commission (the Commission) plans to submit proposals for changes to the EU regulatory framework governing medicines later this year. EFPIA, the European Federation of Pharmaceutical Industries and Associations which represents the innovative pharmaceutical sector, anticipated this significant milestone in the rule-making process by publishing a list of recommendations for regulatory modifications (see, attachment).

    Read more
    • 03/01/2022
    • News

    Catherine Longeval appointed Co-Chair of the International Bar Association (IBA)’s Healthcare & Life Sciences Law Committee

    Van Bael & Bellis is pleased to announce that Catherine L. has been appointed Co-Chair of the International Bar Association (IBA) effective January 1st, 2022. This appointment recognizes the high standing of our firm’s thriving life sciences practice in the international life sciences community. Catherine’s Co-Chair during the first year of her two year mandate is Jonás Bergstein of Bergstein Abogados in Uruguay. Together with a dedicated team of fellow Officers, they are committed to further enhancing the visibility and the work of that Committee, which has a dynamic and diverse membership spanning all continents. The Committee focuses on all aspects of healthcare law, pharmaceutical, biotech and medical devices regulatory law, intellectual property, bioethics and scientific developments across the globe. It provides a forum for discussion among health and life science lawyers and aims to provide regular updates of important changes in this field through newsletters, webinars/seminars and conferences. For more information on the work of the IBA’s Healthcare & Life Sciences Law Committee, please click here.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *